PE20241307A1 - Inhibidores de molecula pequena de proteasa 1 especifica de ubiquitina (usp1) y usos de los mismos - Google Patents
Inhibidores de molecula pequena de proteasa 1 especifica de ubiquitina (usp1) y usos de los mismosInfo
- Publication number
- PE20241307A1 PE20241307A1 PE2024001033A PE2024001033A PE20241307A1 PE 20241307 A1 PE20241307 A1 PE 20241307A1 PE 2024001033 A PE2024001033 A PE 2024001033A PE 2024001033 A PE2024001033 A PE 2024001033A PE 20241307 A1 PE20241307 A1 PE 20241307A1
- Authority
- PE
- Peru
- Prior art keywords
- independently selected
- halo
- optionally substituted
- usp1
- ubiquitin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130290 | 2021-11-12 | ||
| CN2022123827 | 2022-10-08 | ||
| PCT/CN2022/131293 WO2023083286A1 (en) | 2021-11-12 | 2022-11-11 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241307A1 true PE20241307A1 (es) | 2024-06-24 |
Family
ID=86335131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001033A PE20241307A1 (es) | 2021-11-12 | 2022-11-11 | Inhibidores de molecula pequena de proteasa 1 especifica de ubiquitina (usp1) y usos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20250026754A1 (enExample) |
| EP (1) | EP4430050A4 (enExample) |
| JP (1) | JP2024543477A (enExample) |
| KR (1) | KR20240117556A (enExample) |
| CN (1) | CN119053601A (enExample) |
| AR (1) | AR127646A1 (enExample) |
| AU (1) | AU2022386486A1 (enExample) |
| CA (1) | CA3235765A1 (enExample) |
| CL (2) | CL2024001397A1 (enExample) |
| CO (1) | CO2024006269A2 (enExample) |
| CR (1) | CR20240191A (enExample) |
| DO (1) | DOP2024000080A (enExample) |
| GE (1) | GEAP202416532A (enExample) |
| IL (1) | IL312642A (enExample) |
| JO (1) | JOP20240096A1 (enExample) |
| MX (1) | MX2024005755A (enExample) |
| PE (1) | PE20241307A1 (enExample) |
| TW (1) | TW202334142A (enExample) |
| WO (1) | WO2023083286A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127646A1 (es) | 2021-11-12 | 2024-02-14 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| WO2024086790A1 (en) * | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| WO2025227060A1 (en) | 2024-04-26 | 2025-10-30 | Insilico Medicine Ip Limited | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN100340559C (zh) * | 1998-12-23 | 2007-10-03 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为凝血因子xa抑制剂的含氮杂双环 |
| WO2002068419A1 (en) | 2001-02-26 | 2002-09-06 | Tanabe Seiyaku Co., Ltd. | Pyridopyrimidine or naphthyridine derivative |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| ITFR20030005U1 (it) | 2003-03-17 | 2003-06-16 | C D R | Sistema di protezione solare (frangisole f1) |
| JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| JP5063815B2 (ja) | 2008-11-25 | 2012-10-31 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体 |
| MX2012004846A (es) | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| CA2783258A1 (en) | 2009-12-23 | 2011-06-30 | Elan Pharmaceuticals, Inc. | Pteridinones as inhibitors of polo-like kinase |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2013037415A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CN104311555B (zh) | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 吡唑并哌啶酮类化合物及其组合物及用途 |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| MA45146A (fr) | 2016-05-24 | 2021-03-24 | Constellation Pharmaceuticals Inc | Dérivés de pyrazolopyridine pour le traitement du cancer |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2019089216A1 (en) | 2017-11-01 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| AU2019405925B2 (en) * | 2018-12-20 | 2025-07-03 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| US20220073525A1 (en) * | 2018-12-28 | 2022-03-10 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| US20230277533A1 (en) * | 2020-02-14 | 2023-09-07 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| US20230219965A1 (en) | 2020-06-02 | 2023-07-13 | KSQ Therapeutics, Inc. | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
| AU2021371305A1 (en) | 2020-10-30 | 2023-06-15 | KSQ Therapeutics, Inc. | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
| TW202246255A (zh) | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
| EP4291559A1 (en) | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| JP2024511996A (ja) | 2021-03-17 | 2024-03-18 | タンゴ セラピューティクス， インコーポレイテッド | 抗がん剤としてのプリン誘導体 |
| WO2022199652A1 (en) | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| IL307157A (en) | 2021-04-07 | 2023-11-01 | Forma Therapeutics Inc | Ubiquitin-specific protease 1 (USP1) inhibition |
| TW202304933A (zh) | 2021-04-09 | 2023-02-01 | 大陸商海南耀臻生物醫藥科技有限公司 | 泛素特異性蛋白酶１（ｕｓｐ１）抑制劑、藥物組合物及其治療哺乳動物由ｕｓｐ１介導的疾病的方法 |
| CN119173515A (zh) | 2021-11-12 | 2024-12-20 | 英矽智能科技知识产权有限公司 | 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途 |
| PE20241234A1 (es) | 2021-11-12 | 2024-06-19 | Insilico Medicine Ip Ltd | Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos |
| AR127646A1 (es) | 2021-11-12 | 2024-02-14 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
-
2022
- 2022-11-11 AR ARP220103104A patent/AR127646A1/es unknown
- 2022-11-11 MX MX2024005755A patent/MX2024005755A/es unknown
- 2022-11-11 JP JP2024528452A patent/JP2024543477A/ja active Pending
- 2022-11-11 CR CR20240191A patent/CR20240191A/es unknown
- 2022-11-11 TW TW111143088A patent/TW202334142A/zh unknown
- 2022-11-11 IL IL312642A patent/IL312642A/en unknown
- 2022-11-11 CA CA3235765A patent/CA3235765A1/en active Pending
- 2022-11-11 WO PCT/CN2022/131293 patent/WO2023083286A1/en not_active Ceased
- 2022-11-11 AU AU2022386486A patent/AU2022386486A1/en active Pending
- 2022-11-11 KR KR1020247018882A patent/KR20240117556A/ko active Pending
- 2022-11-11 US US18/709,234 patent/US20250026754A1/en not_active Abandoned
- 2022-11-11 CN CN202280087378.2A patent/CN119053601A/zh active Pending
- 2022-11-11 EP EP22892079.9A patent/EP4430050A4/en active Pending
- 2022-11-11 PE PE2024001033A patent/PE20241307A1/es unknown
- 2022-11-11 GE GEAP202416532A patent/GEAP202416532A/en unknown
-
2023
- 2023-02-06 US US18/106,339 patent/US11739077B2/en active Active
- 2023-06-26 US US18/340,978 patent/US12570634B2/en active Active
-
2024
- 2024-04-24 JO JOJO/P/2024/0096A patent/JOP20240096A1/ar unknown
- 2024-05-09 CL CL2024001397A patent/CL2024001397A1/es unknown
- 2024-05-10 DO DO2024000080A patent/DOP2024000080A/es unknown
- 2024-05-17 CO CONC2024/0006269A patent/CO2024006269A2/es unknown
-
2025
- 2025-04-09 CL CL2025001068A patent/CL2025001068A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12570634B2 (en) | 2026-03-10 |
| US20230183210A1 (en) | 2023-06-15 |
| CN119053601A (zh) | 2024-11-29 |
| JP2024543477A (ja) | 2024-11-21 |
| CR20240191A (es) | 2024-09-13 |
| TW202334142A (zh) | 2023-09-01 |
| AU2022386486A1 (en) | 2024-05-09 |
| CO2024006269A2 (es) | 2024-05-30 |
| DOP2024000080A (es) | 2024-11-29 |
| GEAP202416532A (en) | 2024-08-12 |
| US20240190839A1 (en) | 2024-06-13 |
| WO2023083286A1 (en) | 2023-05-19 |
| CL2025001068A1 (es) | 2025-07-11 |
| IL312642A (en) | 2024-07-01 |
| JOP20240096A1 (ar) | 2024-04-24 |
| US11739077B2 (en) | 2023-08-29 |
| AR127646A1 (es) | 2024-02-14 |
| US20250026754A1 (en) | 2025-01-23 |
| CL2024001397A1 (es) | 2024-10-25 |
| EP4430050A4 (en) | 2025-09-24 |
| KR20240117556A (ko) | 2024-08-01 |
| CA3235765A1 (en) | 2023-05-19 |
| EP4430050A1 (en) | 2024-09-18 |
| MX2024005755A (es) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241350A1 (es) | Inhibidores de moleculas pequenas de la proteasa especifica de ubiquitina 1 (usp1) y sus usos | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| MX2025009239A (es) | Compuestos triciclicos para el tratamiento de cancer | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20220140A1 (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| PE20230488A1 (es) | Inhibidores macrociclicos de las peptidilarginina deiminasas | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR049898A1 (es) | Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos | |
| CO2022017618A2 (es) | Antagonistas del receptor de adenosina a2a | |
| UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
| AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
| PE20200342A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| PE20191652A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| PE20181078A1 (es) | Derivados de 8-[6-[3-(amino) propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer | |
| CO2023013321A2 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR057033A1 (es) | Tigeciclina y metodos para preparar 9-nitrominociclina | |
| AR045819A1 (es) | Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| PY2132400A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO |